Print

Purpose

The purpose of this study is to investigate the immunogenicity of mRNA COVID-19 variant-containing vaccine formulations against the vaccine matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously vaccinated adults.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Participants had previous mRNA COVID-19 vaccination. - Able to comply with study procedures based on the assessment of the Investigator. - Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: - Has a negative pregnancy test at the Screening Visit and on the day of vaccination prior to vaccine dose being administered on Day 1. - Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose. - Has agreed to continue adequate contraception through 28 days following vaccine administration.

Exclusion Criteria

  • History of SARS-CoV-2 infection within 3 months prior to enrollment. - Is acutely ill or febrile (temperature 38.0°Celsius/100.4°Fahrenheit) less than 72 hours prior to or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the Screening window. - History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable, or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures. - History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic. - Receipt of COVID-19 vaccine within 3 months prior to enrollment. - Receipt of any licensed non-COVID-19 vaccine within 28 days before or planned receipt within 28 days after the study intervention, except an influenza vaccine, which may be given 14 days before or after receipt of the study intervention. - Receipt of systemic immunosuppressants or immune-modifying drugs for >14 days total, within 6 months prior to Screening or is anticipating the need for immunosuppressive treatment at any time during participation in the study. - Receipt of systemic immunoglobulins or blood products within 3 months prior to the Screening Visit or plans for receipt during the study. - Has donated ≥450 milliliters of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
This is a Phase 3b/4 open-label study.
Primary Purpose
Prevention
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
mRNA-1273 Variant-containing Formulation 		Participants will receive an intramuscular (IM) injection of a mRNA-1273 variant-containing formulation.
  • Biological: mRNA-1273 Variant-containing Formulation
    Sterile liquid for injection

Recruiting Locations

More Details

NCT ID
NCT06585241
Status
Active, not recruiting
Sponsor
ModernaTX, Inc.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.